boron oxoacid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	boron oxoacid	go back to main search page
Accession:	CHEBI:33145	browse the term
Synonyms:	related_synonym:	boron oxoacids; oxoacids of boron

show annotations for term's descendants Sort by:
Rat (901) Mouse (904) Human (931) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (901)

2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

NPHS1 adhesion molecule, nephrin

increases expression

BD4 increases expression of Nphs1 mRNA in podocytes

RGD

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

synaptopodin

increases expression

BD4 increases expression of Synpo mRNA in podocytes

RGD

NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126

boric acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein]

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin alpha 2, smooth muscle

decreases expression

boric acid results in decreased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin, C1Q and collagen domain containing

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

angiotensinogen

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

increases expression

boric acid results in increased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arginase 1

decreases activity

boric acid results in decreased activity of ARG1 protein

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

activating transcription factor 4

increases expression

boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein

PMID:25425213 PMID:27587023

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions

boric acid results in increased cleavage of and affects the localization of ATF6 protein

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

BCL2 associated X, apoptosis regulator

decreases expression
increases expression
multiple interactions

boric acid results in decreased expression of BAX mRNA
boric acid results in increased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein

PMID:31368021 PMID:33137424 PMID:34175401

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
decreases expression
multiple interactions

boric acid results in increased expression of BCL2 mRNA
boric acid results in decreased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein

PMID:31368021 PMID:33137424 PMID:34175401

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

boric acid results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

BH3 interacting domain death agonist

increases expression

boric acid results in increased expression of BID mRNA

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

calreticulin

increases expression

boric acid results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

decreases expression
increases expression
multiple interactions

boric acid results in decreased expression of CASP3 mRNA
boric acid results in increased expression of CASP3 mRNA
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]

PMID:31368021 PMID:31823256 PMID:34175401

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases expression

boric acid results in increased expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
decreases activity

[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]

PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

multiple interactions
increases expression

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
boric acid results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CCAAT/enhancer binding protein alpha

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

collagen type I alpha 2 chain

affects expression

boric acid affects the expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

colony stimulating factor 2

increases expression

boric acid results in increased expression of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

increases expression

boric acid results in increased expression of CSF3 protein

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

cystatin C

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein]

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

catenin beta 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

DNA-damage inducible transcript 3

decreases expression

boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

desmin

affects expression

boric acid affects the expression of DES mRNA

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

dishevelled segment polarity protein 2

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]

NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820

G

ER degradation enhancing alpha-mannosidase like protein 1

increases expression

boric acid results in increased expression of EDEM1 mRNA

NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]

PMID:25425213 PMID:27587023 PMID:30196486

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

fatty acid binding protein 4

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid synthase

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 2

multiple interactions

boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 7

increases expression

boric acid results in increased expression of FGF7 protein

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fibronectin 1

increases expression
affects expression

boric acid results in increased expression of FN1 mRNA
boric acid affects the expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression

boric acid results in decreased expression of GAPDH protein

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

growth arrest specific 6

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

glucokinase

increases expression

boric acid results in increased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression

EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamic--pyruvic transaminase

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

hepatitis A virus cellular receptor 1

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

boric acid results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

heme oxygenase 1

increases expression

boric acid results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homeobox A6

affects expression

boric acid affects the expression of HOXA6 mRNA

NCBI chr 4:81,304,918...81,313,184
Ensembl chr 4:81,306,407...81,308,850

G

homeo box C6

affects expression

boric acid affects the expression of HOXC6 mRNA

NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392

G

heat shock protein family A (Hsp70) member 5

increases expression

boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein

PMID:25425213 PMID:27587023

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interferon gamma

multiple interactions

[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein]

PMID:29913234 PMID:30368975 PMID:32179172 PMID:33137424

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA

PMID:30997025 PMID:32179172

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]

PMID:29913234 PMID:30368975 PMID:30997025 PMID:32179172

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

increases expression
multiple interactions

boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein

PMID:31368021 PMID:33137424

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA

PMID:28285642 PMID:30997025 PMID:32179172

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

increases expression

boric acid results in increased expression of INS1 mRNA

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions
increases expression

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA

PMID:28285642 PMID:31368021

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

KLF transcription factor 5

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

laminin subunit alpha 5

increases expression

boric acid results in increased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

leptin

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase E, hormone sensitive type

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microRNA 130a

decreases expression

boric acid results in decreased expression of MIR130A mRNA

NCBI chr 3:69,822,542...69,822,629
Ensembl chr 3:69,822,542...69,822,629

G

microRNA 200a

decreases expression

boric acid results in decreased expression of MIR200A mRNA

NCBI chr 5:166,648,494...166,648,582

G

microRNA 21

decreases expression

boric acid results in decreased expression of MIR21 mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 224

decreases expression

boric acid results in decreased expression of MIR224 mRNA

NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169

G

matrix metallopeptidase 2

decreases expression

boric acid results in decreased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myosin heavy chain 1

affects expression

boric acid affects the expression of MYH1 mRNA

NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295

G

myogenic differentiation 1

affects expression
decreases expression

boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein

NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554

G

myogenin

affects expression

boric acid affects the expression of MYOG mRNA

NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039

G

NFE2 like bZIP transcription factor 2

affects localization
multiple interactions

boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions
affects expression

boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

increases expression

boric acid results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

proliferating cell nuclear antigen

increases expression
multiple interactions

boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA

PMID:17943231 PMID:33137424

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

pancreatic and duodenal homeobox 1

increases expression

boric acid results in increased expression of PDX1 mRNA

NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064

G

peroxisome proliferator-activated receptor gamma

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 15A

increases expression

boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

prostaglandin-endoperoxide synthase 2

multiple interactions

boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]

PMID:29913234 PMID:30368975

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

affects expression

boric acid affects the expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

solute carrier family 2 member 2

increases expression

boric acid results in increased expression of SLC2A2 mRNA

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 2 member 4

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 4 member 2

increases expression

boric acid results in increased expression of SLC4A2 mRNA

NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965

G

solute carrier family 4 member 3

increases expression

boric acid results in increased expression of SLC4A3 mRNA

NCBI chr 9:77,036,243...77,053,940
Ensembl chr 9:77,037,016...77,049,105

G

secreted protein acidic and cysteine rich

affects expression

boric acid affects the expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

sterol regulatory element binding transcription factor 1

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

synoviolin 1

decreases expression

boric acid results in decreased expression of SYVN1 mRNA

NCBI chr 1:203,339,235...203,346,137
Ensembl chr 1:203,339,619...203,346,152

G

transferrin receptor

multiple interactions

boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

increases expression

boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA

PMID:27206737 PMID:31368021

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions
decreases expression
increases secretion
increases expression

boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA

PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

multiple interactions

boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

tumor protein p53

decreases expression

boric acid results in decreased expression of TRP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

X-box binding protein 1

increases expression

boric acid results in increased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

boric acids

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-glutamyltransferase 1

decreases activity

Boric Acids analog results in decreased activity of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

mucin 1, cell surface associated

decreases expression

Boric Acids results in decreased expression of MUC1 mRNA

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

mucin 16, cell surface associated

decreases expression

Boric Acids results in decreased expression of MUC16 mRNA

NCBI chr 8:16,164,531...16,323,126

bortezomib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 2

decreases expression

Bortezomib results in decreased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases expression
decreases activity

[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein

PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

decreases expression
multiple interactions

Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein

PMID:20977926 PMID:33775688

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression

Bortezomib results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 4

decreases expression

Bortezomib results in decreased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

abhydrolase domain containing 16A, phospholipase

increases expression

Bortezomib results in increased expression of ABHD16A mRNA

NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927

G

abhydrolase domain containing 2, acylglycerol lipase

increases expression

Bortezomib results in increased expression of ABHD2 mRNA

NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061

G

abl-interactor 1

increases expression

Bortezomib results in increased expression of ABI1 mRNA

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions

[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]

PMID:15039284 PMID:17495969 PMID:21195056

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

angiotensin I converting enzyme

multiple interactions

[Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA thioesterase 7

decreases expression

Bortezomib results in decreased expression of ACOT7 mRNA

NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309

G

ADAM metallopeptidase domain 10

decreases expression

Bortezomib results in decreased expression of ADAM10 mRNA

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

adrenomedullin

multiple interactions
decreases expression

Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

ALF transcription elongation factor 1

increases expression

Bortezomib results in increased expression of AFF1 mRNA

NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729

G

ALF transcription elongation factor 4

increases expression

Bortezomib results in increased expression of AFF4 mRNA

NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751

G

AFG2 AAA ATPase homolog A

increases expression

Bortezomib results in increased expression of AFG2A mRNA

NCBI chr 2:120,306,417...120,497,707
Ensembl chr 2:120,306,412...120,497,705

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA]

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

acylglycerol kinase

decreases expression

Bortezomib results in decreased expression of AGK mRNA

NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934

G

agrin

decreases expression

Bortezomib results in decreased expression of AGRN mRNA

NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003

G

ATP/GTP binding carboxypeptidase 1

increases expression

Bortezomib results in increased expression of AGTPBP1 mRNA

NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869

G

angiotensin II receptor-associated protein

decreases expression

Bortezomib results in decreased expression of AGTRAP mRNA

NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036

G

apoptosis inducing factor, mitochondria associated 1

affects localization
multiple interactions

Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein

PMID:12893773 PMID:16024631

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AIF family member 2

increases expression

Bortezomib results in increased expression of AIFM2 mRNA

NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236

G

absent in melanoma 2

increases expression

Bortezomib results in increased expression of AIM2 mRNA

NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975

G

AFG2 interacting ribosome maturation factor

increases expression

Bortezomib results in increased expression of AIRIM mRNA

NCBI chr 5:137,198,688...137,205,912
Ensembl chr 5:137,198,720...137,204,026

G

aldo-keto reductase family 1 member B1

increases expression

Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

increases expression

Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldo-keto reductase family 1, member C1

multiple interactions
increases expression

[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA

PMID:21215737 PMID:25913414

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

affects expression

Bortezomib affects the expression of AKR1C2 mRNA

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

increases expression

Bortezomib results in increased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 7, member A2

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA

NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909

G

AKT serine/threonine kinase 1

multiple interactions
decreases activity
decreases expression

[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein

PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aminolevulinate dehydratase

decreases activity
multiple interactions

Bortezomib results in decreased activity of ALAD protein
Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein]

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

aldehyde dehydrogenase 18 family, member A1

decreases expression

Bortezomib results in decreased expression of ALDH18A1 mRNA

NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890

G

aldehyde dehydrogenase 5 family, member A1

decreases expression

Bortezomib results in decreased expression of ALDH5A1 mRNA

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

Bortezomib results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656

G

arachidonate 12-lipoxygenase, 12S type

increases response to substance

ALOX12 gene SNP results in increased susceptibility to Bortezomib

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

anaphase promoting complex subunit 11

decreases expression

Bortezomib results in decreased expression of ANAPC11 mRNA

NCBI chr10:105,875,209...105,886,307

G

anaphase-promoting complex subunit 5

decreases expression
increases expression

Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA

PMID:17895889 PMID:20977926

NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781

G

ankyrin repeat domain 9

increases expression

Bortezomib results in increased expression of ANKRD9 mRNA

NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923

G

anoctamin 10

increases expression

Bortezomib results in increased expression of ANO10 mRNA

NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670

G

adaptor related protein complex 1 subunit sigma 1

decreases expression

Bortezomib results in decreased expression of AP1S1 mRNA

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

adaptor related protein complex 2 subunit alpha 1

decreases expression

Bortezomib results in decreased expression of AP2A1 mRNA

NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147

G

apolipoprotein B receptor

decreases expression

Bortezomib results in decreased expression of APOBR mRNA

NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528

G

apolipoprotein L9a

decreases expression

Bortezomib results in decreased expression of APOL4 mRNA

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

apolipoprotein O-like

increases expression

Bortezomib results in increased expression of APOOL mRNA

NCBI chr X:77,377,723...77,443,672
Ensembl chr X:77,377,781...77,443,900

G

aquaporin 3 (Gill blood group)

increases expression

Bortezomib results in increased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

androgen receptor

multiple interactions

Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:25752796 PMID:30818834

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ARF GTPase 6

increases expression

Bortezomib results in increased expression of ARF6 mRNA

NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114

G

ARF GTPase activating protein 1

decreases expression

Bortezomib results in decreased expression of ARFGAP1 mRNA

NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933

G

Rho GTPase activating protein 1

decreases expression

Bortezomib results in decreased expression of ARHGAP1 mRNA

NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396

G

Rho GDP dissociation inhibitor alpha

decreases expression

Bortezomib results in decreased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

AT-rich interaction domain 3B

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA

NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318

G

ARF like GTPase 4C

decreases expression

Bortezomib results in decreased expression of ARL4C mRNA

NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513

G

ARF like GTPase 8A

increases expression

Bortezomib results in increased expression of ARL8A mRNA

NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851

G

allregulin

decreases expression

Bortezomib results in decreased expression of ARLN mRNA

NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681

G

arrestin, beta 1

decreases expression

Bortezomib results in decreased expression of ARRB1 mRNA

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

decreases expression

Bortezomib results in decreased expression of ASAP1 mRNA

NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754

G

arginyltransferase 1

increases expression

Bortezomib results in increased expression of ATE1 mRNA

NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908

G

activating transcription factor 2

multiple interactions
increases phosphorylation
increases expression

pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA

PMID:12393500 PMID:20977926

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

increases response to substance
multiple interactions
increases expression

ATF3 results in increased susceptibility to Bortezomib
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein

PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
increases expression
decreases response to substance

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib

PMID:15509775 PMID:16928686 PMID:20022965

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 5

increases expression

Bortezomib results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

autophagy related 5

multiple interactions

ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

ATM serine/threonine kinase

multiple interactions
increases cleavage

[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase Na+/K+ transporting subunit alpha 3

decreases expression

Bortezomib results in decreased expression of ATP1A3 mRNA

NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions
affects response to substance

ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

G

ATPase H+ transporting V0 subunit e1

increases expression

Bortezomib results in increased expression of ATP6V0E1 mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

beta-2 microglobulin

decreases expression

Bortezomib results in decreased expression of B2M protein

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2

decreases expression

Bortezomib results in decreased expression of B3GNT2 mRNA

NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273

G

beta-1,4-galactosyltransferase 6

increases expression

Bortezomib results in increased expression of B4GALT6 mRNA

NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247

G

BAG cochaperone 3

increases expression

Bortezomib results in increased expression of BAG3 mRNA

PMID:15509775 PMID:17659339 PMID:20471514

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL2-antagonist/killer 1

multiple interactions
increases expression

[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein

PMID:12902978 PMID:17326159 PMID:20850924

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BRCA1 associated RING domain 1

increases response to substance

BARD1 mutant form results in increased susceptibility to Bortezomib

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein

PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression

Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein

PMID:17898295 PMID:20051518

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

bublin coiled coil protein

decreases expression

Bortezomib results in decreased expression of BBLN mRNA

NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases cleavage
increases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein

PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

multiple interactions
increases expression

[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein

PMID:18223231 PMID:20051518

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

multiple interactions
decreases response to substance
increases cleavage
increases expression
decreases expression

[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
BCL2L1 protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of BCL2L1 protein
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein

PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More...

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions
increases expression
increases activity
increases response to substance

[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib

PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More...

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

Bcl2-like 2

increases expression

Bortezomib results in increased expression of BCL2L2 mRNA

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

BCL3, transcription coactivator

multiple interactions
decreases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA

PMID:20471514 PMID:20977926

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL6, transcription repressor

increases expression

Bortezomib results in increased expression of BCL6 mRNA

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

BAF chromatin remodeling complex subunit BCL7A

decreases expression

Bortezomib results in decreased expression of BCL7A mRNA

NCBI chr12:33,211,978...33,243,903
Ensembl chr12:33,223,931...33,243,886

G

BCR activator of RhoGEF and GTPase

decreases expression

Bortezomib results in decreased expression of BCR mRNA

NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016

G

beclin 1

multiple interactions
decreases response to substance

BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

increases cleavage
multiple interactions

Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]

PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More...

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

BCL2-interacting killer

increases response to substance
increases expression
increases activity

BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein

PMID:16446371 PMID:18566236

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

bridging integrator 1

increases expression

Bortezomib results in increased expression of BIN1 mRNA

NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263

G

baculoviral IAP repeat-containing 2

decreases expression
multiple interactions

Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein

PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases expression
increases expression
multiple interactions

Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA

PMID:17626072 PMID:24085292 PMID:25522274

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions
increases expression

Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein

PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More...

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

baculoviral IAP repeat-containing 7

multiple interactions
decreases expression

arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA]

NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606

G

basophilic leukemia expressed protein BLES03

decreases expression

Bortezomib results in decreased expression of C11ORF68 mRNA

NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804

G

BLK proto-oncogene, Src family tyrosine kinase

decreases expression

Bortezomib results in decreased expression of BLK mRNA

NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031

G

biliverdin reductase B

increases expression

Bortezomib results in increased expression of BLVRB mRNA

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

BCL2 interacting protein 3

increases expression

Bortezomib results in increased expression of BNIP3 protein

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BRCA1, DNA repair associated

decreases expression
increases response to substance
decreases ubiquitination
multiple interactions

Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 mutant form results in increased susceptibility to Bortezomib
Bortezomib results in decreased ubiquitination of BRCA1 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
BRCA1 gene mutant form results in increased susceptibility to Bortezomib
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]

PMID:21917757 PMID:25522274

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

decreases expression
multiple interactions

Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA

PMID:21917757 PMID:25913414

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

BRCA1/BRCA2-containing complex subunit 3

decreases expression

Bortezomib results in decreased expression of BRCC3 mRNA

NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080

G

BRF2 general transcription factor 3B subunit

increases expression

Bortezomib results in increased expression of BRF2 mRNA

NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059

G

BSD domain containing 1

increases expression

Bortezomib results in increased expression of BSDC1 mRNA

NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092

G

similar to human chromosome 6 open reading frame 62

increases expression

Bortezomib results in increased expression of C6ORF62 mRNA

NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020

G

similar to human chromosome 9 open reading frame 85

increases expression

Bortezomib results in increased expression of C9ORF85 mRNA

NCBI chr 1:219,136,085...219,197,723
Ensembl chr 1:219,138,201...219,198,435

G

similar to human chromosome 14 open reading frame 132

decreases expression

Bortezomib results in decreased expression of C14ORF132 mRNA

NCBI chr 6:124,365,466...124,398,449

G

caspase activity and apoptosis inhibitor 1

increases expression

Bortezomib results in increased expression of CAAP1 mRNA

NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314

G

calcium voltage-gated channel subunit alpha1 H

decreases degradation

Bortezomib results in decreased degradation of CACNA1H protein

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calreticulin

multiple interactions
increases expression

[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calpain 15

decreases expression

Bortezomib results in decreased expression of CAPN15 mRNA

NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508

G

carbonic anhydrase 9

decreases expression

Bortezomib results in decreased expression of CA9 protein

NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838

G

caspase recruitment domain family, member 9

multiple interactions

[arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA

NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237

G

caspase 12

increases cleavage

Bortezomib results in increased cleavage of CASP12 protein

PMID:15509775 PMID:16357177

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 2

multiple interactions
increases response to substance
increases cleavage

benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein

PMID:15509775 PMID:16446371 PMID:18723477

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

increases activity
increases cleavage
increases expression
multiple interactions

Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
Bortezomib results in increased expression of CASP3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]

PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

multiple interactions
increases response to substance
increases cleavage
increases activity

[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein

PMID:16357177 PMID:18641367

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

caspase 6

multiple interactions
increases cleavage

Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein]

PMID:16617327 PMID:17510429

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases cleavage
increases activity

[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein

PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More...

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions
increases cleavage

[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]

PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More...

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases expression
increases response to substance
increases cleavage

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib

PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases expression
multiple interactions

Bortezomib results in decreased expression of CAT protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Cbl proto-oncogene

multiple interactions

[Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]

NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176

G

carbonyl reductase 3

increases expression

[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA

PMID:20806931 PMID:20977926

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

chromobox 3

increases expression

Bortezomib results in increased expression of CBX3 mRNA

NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283
Ensembl chr 4:80,546,010...80,559,283

G

cell division cycle and apoptosis regulator 1

increases expression

Bortezomib results in increased expression of CCAR1 protein

PMID:21594647 PMID:21903591

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

coiled-coil domain containing 186

increases expression

Bortezomib results in increased expression of CCDC186 mRNA

NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935

G

coiled-coil domain containing 32

increases expression

Bortezomib results in increased expression of CCDC32 mRNA

NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975

G

coiled-coil domain containing 6

decreases expression

Bortezomib results in decreased expression of CCDC6 mRNA

NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658

G

coiled-coil domain containing 82

increases expression

Bortezomib results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 2

decreases expression

Bortezomib results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression
decreases expression

Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA

PMID:18089816 PMID:20830808

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cyclin B1

multiple interactions
increases expression

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein

PMID:19074855 PMID:20367638 PMID:25522274

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions

[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein]

PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

decreases expression

Bortezomib results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin F

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA

NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101

G

cyclin G2

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

cell cycle progression 1

increases expression

Bortezomib results in increased expression of CCPG1 mRNA

PMID:20471514 PMID:20977926

NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430

G

CD27 molecule

increases expression

Bortezomib results in increased expression of CD27 mRNA

NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592

G

CD38 molecule

decreases expression

Bortezomib results in decreased expression of CD38 mRNA

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

Cd5 molecule

decreases expression

Bortezomib results in decreased expression of CD5 mRNA

NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313

G

Cd69 molecule

increases expression

Bortezomib results in increased expression of CD69 mRNA

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

CD79a molecule

decreases expression

Bortezomib results in decreased expression of CD79A mRNA

NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935

G

Cd82 molecule

decreases expression

Bortezomib results in decreased expression of CD82 mRNA

NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809

G

CD9 molecule

increases expression

Bortezomib results in increased expression of CD9 mRNA

NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222

G

cell division cycle 23

increases expression

Bortezomib results in increased expression of CDC23 mRNA

NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163

G

cell division cycle 34, ubiqiutin conjugating enzyme

increases expression

Bortezomib results in increased expression of CDC34 mRNA

NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186

G

cell division cycle 37, HSP90 cochaperone

increases expression

Bortezomib results in increased expression of CDC37 mRNA

NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809

G

cell division cycle 42

decreases expression

Bortezomib results in decreased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

CDC42 small effector 2

decreases expression

Bortezomib results in decreased expression of CDC42SE2 mRNA

NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
Ensembl chr 1:38,836,555...38,905,059

G

cyclin-dependent kinase 1

multiple interactions
decreases activity
increases activity
increases phosphorylation

Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in decreased activity of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in increased phosphorylation of CDK1 protein

PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions
decreases activity

Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases stability
multiple interactions
decreases response to substance
increases expression

Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein

PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases stability
increases expression

[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein

PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More...

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

chromatin licensing and DNA replication factor 1

decreases expression

Bortezomib results in decreased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CCAAT/enhancer binding protein alpha

multiple interactions

Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions
decreases expression
increases expression

1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
Bortezomib results in decreased expression of CEBPB mRNA
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]

PMID:20471514 PMID:20830808 PMID:30482226

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

centromere protein C

increases expression

Bortezomib results in increased expression of CENPC mRNA

NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476

G

centrosomal protein 290

increases expression

Bortezomib results in increased expression of CEP290 mRNA

NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392

G

ceramide synthase 2

multiple interactions

Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]

NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314

G

ceramide synthase 6

multiple interactions

Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]

NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848

G

CASP8 and FADD-like apoptosis regulator

affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression

Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form

PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More...

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

cell growth regulator with EF hand domain 1

increases expression

Bortezomib results in increased expression of CGREF1 mRNA

NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

increases expression

Bortezomib results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

chromatin assembly factor 1 subunit A

decreases expression

Bortezomib results in decreased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromodomain helicase DNA binding protein 2

increases expression

Bortezomib results in increased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

checkpoint with forkhead and ring finger domains

decreases expression

Bortezomib results in decreased expression of CHFR mRNA

NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014

G

carbohydrate sulfotransferase 11

decreases expression

Bortezomib results in decreased expression of CHST11 mRNA

NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111

G

carbohydrate sulfotransferase 2

decreases expression

Bortezomib results in decreased expression of CHST2 mRNA

NCBI chr 8:95,960,067...95,966,312
Ensembl chr 8:95,959,826...95,966,955

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression
increases activity

Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein

PMID:20471514 PMID:24085292

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

cell death-inducing DFFA-like effector b

decreases expression

Bortezomib results in decreased expression of CIDEB mRNA

NCBI chr15:29,252,208...29,256,482
Ensembl chr15:29,252,213...29,256,605

G

ciliogenesis associated kinase 1

increases expression

Bortezomib results in increased expression of CILK1 mRNA

NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691

G

C-type lectin domain containing 7A

increases expression

Bortezomib results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

CAP-GLY domain containing linker protein family, member 4

increases expression

Bortezomib results in increased expression of CLIP4 mRNA

NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874

G

CLN6, transmembrane ER protein

decreases expression

Bortezomib results in decreased expression of CLN6 mRNA

NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

Bortezomib results in decreased expression of CLPTM1 mRNA

NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092

G

clusterin

increases expression

Bortezomib results in increased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

cytochrome c oxidase subunit 8A

decreases expression

Bortezomib results in decreased expression of COX8A mRNA

NCBI chr 1:204,402,118...204,404,439

G

carnitine palmitoyltransferase 1c

increases response to substance

CPT1C gene SNP results in increased susceptibility to Bortezomib

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

cAMP responsive element binding protein 1

decreases expression
multiple interactions

Bortezomib results in decreased expression of CREB1 protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

decreases expression

Bortezomib results in decreased expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cAMP responsive element modulator

increases expression

Bortezomib results in increased expression of CREM mRNA

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

cysteine-rich protein 2

decreases expression

Bortezomib results in decreased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

cripto, EGF-CFC family member

increases expression

Bortezomib results in increased expression of CRIPTO mRNA

NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308

G

CRK like proto-oncogene, adaptor protein

multiple interactions

[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein

NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238

G

crystallin, alpha B

multiple interactions
increases expression

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA

PMID:20830808 PMID:25522274

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

cystatin F

increases expression

Bortezomib results in increased expression of CST7 mRNA

NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557

G

CTD small phosphatase like 2

decreases expression

Bortezomib results in decreased expression of CTDSPL2 mRNA

NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227

G

cystathionine gamma-lyase

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

catenin beta 1

multiple interactions
decreases response to substance
increases expression

2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]

PMID:18485479 PMID:19100720

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin B

multiple interactions
increases localization

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

increases expression

Bortezomib results in increased expression of CTSD mRNA

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cullin 1

increases expression

Bortezomib results in increased expression of CUL1 mRNA

NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980

G

cullin 3

decreases expression

Bortezomib results in decreased expression of CUL3 mRNA

NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462

G

CWF19 like cell cycle control factor 1

decreases expression

Bortezomib results in decreased expression of CWF19L1 mRNA

NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961

G

C-X-C motif chemokine ligand 1

increases expression

Bortezomib results in increased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]

PMID:20830808 PMID:27194111

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA

PMID:15509775 PMID:27194111

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 4

decreases expression

Bortezomib results in decreased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b5 reductase 1

increases expression

Bortezomib results in increased expression of CYB5R1 mRNA

NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458

G

cytochrome b-245 alpha chain

decreases expression

Bortezomib results in decreased expression of CYBA mRNA

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome c, somatic

multiple interactions
affects localization

[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein

PMID:12893773 PMID:16024631

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects metabolic processing

CYP1A2 protein affects the metabolism of Bortezomib

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

affects metabolic processing

CYP2C19 protein affects the metabolism of Bortezomib

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing

CYP2D6 protein affects the metabolism of Bortezomib

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily u, polypeptide 1

increases expression

Bortezomib results in increased expression of CYP2U1 mRNA

NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing

CYP3A4 protein affects the metabolism of Bortezomib

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytohesin 1 interacting protein

increases expression

Bortezomib results in increased expression of CYTIP mRNA

NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993

G

death associated protein 3

increases expression

Bortezomib results in increased expression of DAP3 mRNA

NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461

G

death-associated protein kinase 2

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA

NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567

G

DAZ associated protein 2

decreases expression

Bortezomib results in decreased expression of DAZAP2 mRNA

NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265

G

drebrin 1

increases expression

Bortezomib results in increased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 11

decreases expression

Bortezomib results in decreased expression of DCAF11 mRNA

NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669

G

DDB1 and CUL4 associated factor 13

increases expression

Bortezomib results in increased expression of DCAF13 mRNA

NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142

G

decapping enzyme, scavenger

decreases expression

Bortezomib results in decreased expression of DCPS mRNA

NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389

G

DNA-damage inducible transcript 3

multiple interactions
increases expression
decreases response to substance

1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib

PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More...

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DEAD/H-box helicase 11

decreases expression

Bortezomib results in decreased expression of DDX11 mRNA

NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550

G

DEAF1 transcription factor

decreases expression

Bortezomib results in decreased expression of DEAF1 mRNA

NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541

G

death effector domain containing 2

increases expression

Bortezomib results in increased expression of DEDD2 mRNA

NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714

G

DEF6 guanine nucleotide exchange factor

decreases expression

Bortezomib results in decreased expression of DEF6 mRNA

NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961

G

DENN domain containing 4A

increases expression

Bortezomib results in increased expression of DENND4A mRNA

NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330

G

DENN domain containing 4B

increases expression

Bortezomib results in increased expression of DENND4B mRNA

NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426

G

DENN domain containing 4C

increases expression

Bortezomib results in increased expression of DENND4C mRNA

NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118

G

diacylglycerol kinase epsilon

decreases expression

Bortezomib results in decreased expression of DGKE mRNA

NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100

G

diablo, IAP-binding mitochondrial protein

affects localization
increases localization
increases expression
multiple interactions

Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]

PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More...

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

DLG associated protein 5

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA

NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518

G

dynein, axonemal, assembly factor 5

decreases expression

Bortezomib results in decreased expression of DNAAF5 mRNA

NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

Bortezomib results in increased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member C14

decreases expression

Bortezomib results in decreased expression of DNAJC14 mRNA

NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645

G

DnaJ heat shock protein family (Hsp40) member C4

decreases expression

Bortezomib results in decreased expression of DNAJC4 mRNA

NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387

G

dynamin 2

decreases expression

Bortezomib results in decreased expression of DNM2 mRNA

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dpy-19 like 4

increases expression

Bortezomib results in increased expression of DPY19L4 mRNA

NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912

G

dystonin

increases expression

Bortezomib results in increased expression of DST mRNA

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

dual specificity phosphatase 15

decreases expression

Bortezomib results in decreased expression of DUSP15 mRNA

NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999

G

dual specificity phosphatase 4

decreases expression

Bortezomib results in decreased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 5

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dynein cytoplasmic 1 intermediate chain 1

increases expression

Bortezomib results in increased expression of DYNC1I1 mRNA

NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149

G

E2F transcription factor 1

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

Ecm29 proteasome adaptor and scaffold

increases expression

Bortezomib results in increased expression of ECPAS mRNA

NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860

G

EDAR associated via death domain

increases expression

Bortezomib results in increased expression of EDARADD mRNA

NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447

G

egl-9 family hypoxia-inducible factor 3

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA

NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766

G

early growth response 1

increases expression

Bortezomib results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

decreases expression

Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

euchromatic histone lysine methyltransferase 2

decreases expression

Bortezomib results in decreased expression of EHMT2 mRNA

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 1

increases expression

Bortezomib results in increased expression of EIF1 mRNA

NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
Ensembl chr 5:85,246,764...85,427,327

G

eukaryotic translation initiation factor 2A

decreases phosphorylation

Bortezomib results in decreased phosphorylation of EIF2A protein

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation
multiple interactions
decreases response to substance

Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib

PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]

PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 2 subunit gamma

decreases expression

Bortezomib results in decreased expression of EIF2S3 mRNA

NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

[trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

eukaryotic translation initiation factor 5A

decreases expression

Bortezomib results in decreased expression of EIF5A mRNA

NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656

G

elongator acetyltransferase complex subunit 5

decreases expression

Bortezomib results in decreased expression of ELP5 mRNA

NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923

G

enolase 2

increases expression

Bortezomib results in increased expression of ENO2 mRNA

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

Eph receptor A1

decreases expression

Bortezomib results in decreased expression of EPHA1 mRNA

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

Eph receptor B2

decreases expression

Bortezomib results in decreased expression of EPHB2 mRNA

NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation

Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

ERCC excision repair 3, TFIIH core complex helicase subunit

increases response to substance

ERCC3 gene SNP results in increased susceptibility to Bortezomib

NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329

G

ERCC excision repair 4, endonuclease catalytic subunit

increases response to substance

ERCC4 gene SNP results in increased susceptibility to Bortezomib

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
Ensembl chr10:2,419,038...2,448,369

G

ER lipid raft associated 2

decreases expression

Bortezomib results in decreased expression of ERLIN2 mRNA

NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
decreases response to substance

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein]
ERN1 results in decreased susceptibility to Bortezomib

PMID:16357177 PMID:22262760 PMID:25522274

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ESF1 nucleolar pre-rRNA processing protein homolog

increases expression

Bortezomib results in increased expression of ESF1 mRNA

NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817

G

estrogen receptor 1

multiple interactions

Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

PMID:25752796 PMID:30818834

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

PMID:25752796 PMID:25913414 PMID:30818834

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

estrogen related receptor, alpha

decreases expression
multiple interactions

Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]

PMID:20977926 PMID:30818834

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

extended synaptotagmin 2

decreases expression

Bortezomib results in decreased expression of ESYT2 mRNA

NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590

G

ETS variant transcription factor 4

decreases expression

Bortezomib results in decreased expression of ETV4 mRNA

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

F2R like trypsin receptor 1

decreases expression

Bortezomib results in decreased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

coagulation factor III, tissue factor

increases expression
multiple interactions

Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid desaturase 2

decreases expression

Bortezomib results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas associated factor 1

increases expression

Bortezomib results in increased expression of FAF1 mRNA

NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977

G

family with sequence similarity 118, member B

increases expression

Bortezomib results in increased expression of FAM118B mRNA

NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270

G

family with sequence similarity 168, member A

increases expression

Bortezomib results in increased expression of FAM168A mRNA

NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220

G

FAM20B, glycosaminoglycan xylosylkinase

decreases expression

Bortezomib results in decreased expression of FAM20B mRNA

NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915

G

family with sequence similarity 219, member A

increases expression

Bortezomib results in increased expression of FAM219A mRNA

NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924

G

family with sequence similarity 241 member B

increases expression

Bortezomib results in increased expression of FAM241B mRNA

NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
Ensembl chr 6:30,052,324...30,055,084

G

family with sequence similarity 43, member A

decreases expression

Bortezomib results in decreased expression of FAM43A mRNA

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401

G

family with sequence similarity 76, member A

increases expression

Bortezomib results in increased expression of FAM76A mRNA

NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574

G

FA complementation group D2

decreases expression

Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein

PMID:19934314 PMID:21917757

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

phenylalanyl-tRNA synthetase subunit alpha

decreases expression

Bortezomib results in decreased expression of FARSA mRNA

NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980

G

Fas cell surface death receptor

multiple interactions
decreases expression
increases expression

[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein

PMID:17351739 PMID:20471514 PMID:25913414

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression

[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein

PMID:17351739 PMID:20471514

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

Fas-activated serine/threonine kinase

decreases expression

Bortezomib results in decreased expression of FASTK mRNA

NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430

G

fibulin 5

decreases expression

Bortezomib results in decreased expression of FBLN5 mRNA

NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755

G

F-box and WD repeat domain containing 7

decreases expression

Bortezomib results in decreased expression of FBXW7 mRNA

NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941

G

fibroblast growth factor 21

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

FGFR1 oncogene partner 2

increases expression

Bortezomib results in increased expression of FGFR1OP2 mRNA

NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630

G

FKBP prolyl isomerase 1A

decreases expression

Bortezomib results in decreased expression of FKBP1A mRNA

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 5

decreases expression

Bortezomib results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

folliculin

increases expression

Bortezomib results in increased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

fragile X messenger ribonucleoprotein 1

decreases expression

Bortezomib results in decreased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

folate receptor alpha

decreases expression

Bortezomib results in decreased expression of FOLR1 mRNA

NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667

G

forkhead box A1

multiple interactions
decreases expression

[arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA

PMID:20471514 PMID:25913414

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

FRY microtubule binding protein

increases expression

Bortezomib results in increased expression of FRY mRNA

NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116

G

fibronectin type III and SPRY domain containing 1-like

increases expression

Bortezomib results in increased expression of FSD1L mRNA

NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928

G

frizzled class receptor 2

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

glucose-6-phosphate dehydrogenase

decreases expression

Bortezomib results in decreased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

GABA type A receptor associated protein like 1

increases expression

Bortezomib results in increased expression of GABARAPL1 mRNA

NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450

G

growth arrest and DNA-damage-inducible, alpha

increases expression
multiple interactions

Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA

PMID:20830808 PMID:20977926 PMID:25522274

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

increases expression
multiple interactions

Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]

PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

increases expression

Bortezomib results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

polypeptide N-acetylgalactosaminyltransferase 4

increases expression

Bortezomib results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

glucosidase II alpha subunit

decreases expression

Bortezomib results in decreased expression of GANAB mRNA

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

growth arrest specific 7

decreases expression

Bortezomib results in decreased expression of GAS7 mRNA

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

guanylate binding protein 2

increases expression

Bortezomib results in increased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Bortezomib results in increased expression of GCLC mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

Bortezomib results in increased expression of GCLM mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 2

increases expression

Bortezomib results in increased expression of GCNT2 mRNA

NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611

G

growth differentiation factor 15

increases expression
multiple interactions

Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA

PMID:20830808 PMID:25522274

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glial fibrillary acidic protein

multiple interactions
increases expression

Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

growth hormone receptor

increases expression

Bortezomib results in increased expression of GHR mRNA

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

GIT ArfGAP 1

decreases expression

Bortezomib results in decreased expression of GIT1 mRNA

NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373

G

G kinase anchoring protein 1

increases expression

Bortezomib results in increased expression of GKAP1 mRNA

NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679

G

galactosidase, alpha

increases expression

Bortezomib results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

galactosidase, beta 1

multiple interactions
increases expression

TERT protein inhibits the reaction [Bortezomib results in increased expression of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

G protein subunit alpha i3

increases expression

Bortezomib results in increased expression of GNAI3 mRNA

NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742

G

golgi SNAP receptor complex member 2

increases expression

Bortezomib results in increased expression of GOSR2 mRNA

NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625

G

G patch domain and ankyrin repeats 1

increases expression

Bortezomib results in increased expression of GPANK1 mRNA

NCBI chr20:3,697,641...3,700,814
Ensembl chr20:3,697,641...3,700,858

G

glycerol-3-phosphate acyltransferase 3

increases expression

Bortezomib results in increased expression of GPAT3 mRNA

NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490

G

G patch domain containing 2-like

increases expression

Bortezomib results in increased expression of GPATCH2L mRNA

NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888

G

gephyrin

decreases expression

Bortezomib results in decreased expression of GPHN mRNA

NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612

G

G protein-coupled receptor 157

decreases expression

Bortezomib results in decreased expression of GPR157 mRNA

NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432

G

G-protein signaling modulator 3

decreases expression

Bortezomib results in decreased expression of GPSM3 mRNA

NCBI chr20:4,157,123...4,158,984
Ensembl chr20:4,157,123...4,159,035

G

glycogen synthase kinase 3 alpha

multiple interactions

[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form

NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802

G

glycogen synthase kinase 3 beta

multiple interactions

[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein]

PMID:16118318 PMID:24085292

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

G1 to S phase transition 1

decreases expression

Bortezomib results in decreased expression of GSPT1 mRNA

NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198

G

glutathione-disulfide reductase

increases expression

Bortezomib results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase, C-terminal domain containing

decreases expression

Bortezomib results in decreased expression of GSTCD mRNA

NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857

G

glutathione S-transferase mu 4

decreases expression

Bortezomib results in decreased expression of GSTM4 mRNA

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

general transcription factor IIIC subunit 2

decreases expression

Bortezomib results in decreased expression of GTF3C2 mRNA

NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490

G

GTP binding protein 1

decreases expression

Bortezomib results in decreased expression of GTPBP1 mRNA

NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705

G

granzyme A

decreases expression

Bortezomib results in decreased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

granzyme B

increases expression

Bortezomib results in increased expression of GZMB mRNA

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

H2A.X variant histone

multiple interactions
decreases phosphorylation
increases expression

[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]

PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)

decreases expression

Bortezomib results in decreased expression of H6PD mRNA

NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

increases expression

Bortezomib results in increased expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

HAUS augmin like complex subunit 6

increases expression

Bortezomib results in increased expression of HAUS6 mRNA

NCBI chr 5:101,116,532...101,156,396
Ensembl chr 5:101,119,300...101,153,124

G

histone deacetylase 10

decreases expression

Bortezomib results in decreased expression of HDAC10 mRNA

NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228

G

histone deacetylase 4

decreases expression

Bortezomib results in decreased expression of HDAC4 mRNA

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

histone deacetylase 6

decreases response to substance

HDAC6 results in decreased susceptibility to Bortezomib

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

HECT domain E3 ubiquitin protein ligase 2

increases expression

Bortezomib results in increased expression of HECTD2 mRNA

NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487

G

HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA

NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720

G

hexosaminidase D

decreases expression

Bortezomib results in decreased expression of HEXD mRNA

NCBI chr10:106,479,781...106,498,799
Ensembl chr10:106,480,194...106,498,799

G

hypoxia inducible factor 1 subunit alpha

increases expression

Bortezomib results in increased expression of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heat shock protein nuclear import factor hikeshi

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA

NCBI chr 1:143,825,399...143,849,361
Ensembl chr 1:143,825,923...143,849,363

G

histone cluster 1 H2a family member I like 1

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA

NCBI chr17:41,568,181...41,569,093
Ensembl chr17:41,568,471...41,569,109

G

heme oxygenase 1

multiple interactions
increases expression
increases response to substance

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
HMOX1 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein

PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

multiple interactions

abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA]

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heterogeneous nuclear ribonucleoprotein L-like

increases expression

Bortezomib results in increased expression of HNRNPLL mRNA

NCBI chr 6:14,969,953...15,000,574
Ensembl chr 6:14,970,057...14,999,745

G

homeobox A11

decreases expression

Bortezomib results in decreased expression of HOXA11 mRNA

NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232

G

HPS3, biogenesis of lysosomal organelles complex 2 subunit 1

decreases expression

Bortezomib results in decreased expression of HPS3 mRNA

NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047

G

HRas proto-oncogene, GTPase

multiple interactions

ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

heat shock transcription factor 1

increases expression
increases activity
multiple interactions

Bortezomib results in increased expression of HSF1 mRNA
Bortezomib results in increased activity of HSF1 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]

PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock transcription factor 2

increases expression
multiple interactions

Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein
HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]

NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174

G

heat shock protein 90 alpha family class A member 1

increases expression
decreases expression

Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA

PMID:17895889 PMID:20471514 PMID:20830808

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

increases expression

Bortezomib results in increased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 1A

multiple interactions
decreases response to substance
increases expression

Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA

PMID:17895889 PMID:23874968

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1B

increases expression
affects response to substance
decreases response to substance

Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib

PMID:15509775 PMID:17895889 PMID:23874968

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 4 like

increases expression

Bortezomib results in increased expression of HSPA4L mRNA

NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression
decreases response to substance

Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5 mRNA
HSPA5 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein

PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 More...

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

Bortezomib results in increased expression of HSPA6 mRNA

PMID:15509775 PMID:17898295 PMID:20977926

NCBI chr13:83,273,176...83,274,317

G

heat shock protein family B (small) member 1

increases expression
decreases response to substance

Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib

PMID:14559800 PMID:20830808

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family H (Hsp110) member 1

increases expression

Bortezomib results in increased expression of HSPH1 mRNA

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

5-hydroxytryptamine receptor 2B

decreases expression

Bortezomib results in decreased expression of HTR2B mRNA

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

HtrA serine peptidase 2

affects localization

Bortezomib affects the localization of HTRA2 protein

NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095

G

inhibitor of Bruton tyrosine kinase

increases expression

Bortezomib results in increased expression of IBTK mRNA

NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA

PMID:18223231 PMID:20471514 PMID:25913414

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

insulin degrading enzyme

increases expression

Bortezomib results in increased expression of IDE mRNA

NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

decreases expression

Bortezomib results in decreased expression of IDH3A mRNA

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084

G

interferon-induced protein 44

increases expression

Bortezomib results in increased expression of IFI44 mRNA

NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844

G

interferon induced transmembrane protein 1

decreases expression

Bortezomib results in decreased expression of IFITM1 mRNA

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169

G

interferon gamma

multiple interactions

[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon-related developmental regulator 2

decreases expression

Bortezomib results in decreased expression of IFRD2 mRNA

NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194

G

insulin-like growth factor 1 receptor

increases response to substance

IGF1R gene SNP results in increased susceptibility to Bortezomib

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor 2

multiple interactions
decreases response to substance

Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions
decreases expression

Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA

PMID:19417023 PMID:20471514 PMID:24085292

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

IKAROS family zinc finger 1

decreases expression

Bortezomib results in decreased expression of IKZF1 mRNA

NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416

G

interleukin 10

affects expression

Bortezomib affects the expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 15

increases expression

Bortezomib results in increased expression of IL15 mRNA

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 18 receptor 1

increases expression

Bortezomib results in increased expression of IL18R1 mRNA

NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715

G

interleukin 1 beta

increases expression
multiple interactions

Bortezomib results in increased expression of IL1B mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

increases expression

Bortezomib results in increased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 23 subunit alpha

increases expression

Bortezomib results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 6

multiple interactions
increases expression
decreases expression
decreases secretion

[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib results in increased expression of IL6 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in decreased secretion of IL6 protein

PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7 receptor

increases expression
multiple interactions

Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA

PMID:20471514 PMID:25522274

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

INO80 complex subunit B

decreases expression

Bortezomib results in decreased expression of INO80B mRNA

NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456

G

interleukin-1 receptor-associated kinase 1

decreases expression

Bortezomib results in decreased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

interleukin-1 receptor-associated kinase 2

increases expression

Bortezomib results in increased expression of IRAK2 mRNA

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602

G

interferon regulatory factor 4

multiple interactions
decreases expression

3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein]

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

insulin receptor substrate 1

decreases degradation

Bortezomib results in decreased degradation of IRS1 protein

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

iron-sulfur cluster assembly 1

increases expression

Bortezomib results in increased expression of ISCA1 mRNA

NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955

G

integrin subunit alpha 6

decreases expression

Bortezomib results in decreased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit alpha L

decreases expression

Bortezomib results in decreased expression of ITGAL mRNA

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit alpha V

multiple interactions
increases expression

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA

PMID:20471514 PMID:25913414

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 6

increases expression

Bortezomib results in increased expression of ITGB6 mRNA

NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671

G

Janus kinase 1

decreases expression

Bortezomib results in decreased expression of JAK1 mRNA

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression
increases phosphorylation
multiple interactions

Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
Bortezomib results in increased phosphorylation of JUN protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]

PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 More...

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

decreases expression
multiple interactions

Bortezomib results in decreased expression of JUNB protein
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

JunD proto-oncogene, AP-1 transcription factor subunit

decreases expression

Bortezomib results in decreased expression of JUND mRNA

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

lysine acetyltransferase 2B

decreases expression

Bortezomib results in decreased expression of KAT2B mRNA

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

lysine acetyltransferase 6B

decreases expression

Bortezomib results in decreased expression of KAT6B mRNA

NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316

G

katanin catalytic subunit A1 like 1

increases expression

Bortezomib results in increased expression of KATNAL1 mRNA

NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553

G

potassium channel modulatory factor 1

increases expression

Bortezomib results in increased expression of KCMF1 mRNA

NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234

G

potassium channel tetramerization domain containing 10

increases expression

Bortezomib results in increased expression of KCTD10 mRNA

NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783

G

KDEL endoplasmic reticulum protein retention receptor 1

decreases expression

Bortezomib results in decreased expression of KDELR1 mRNA

NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157

G

lysine demethylase 4B

decreases expression

Bortezomib results in decreased expression of KDM4B mRNA

NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543

G

lysine demethylase 5C

decreases expression

Bortezomib results in decreased expression of KDM5C mRNA

NCBI chr X:21,345,459...21,387,045
Ensembl chr X:21,345,481...21,381,870

G

kinase insert domain receptor

multiple interactions

[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

kinesin family member 22

decreases expression

Bortezomib results in decreased expression of KIF22 mRNA

NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401

G

kinesin family member 9

decreases expression

Bortezomib results in decreased expression of KIF9 mRNA

NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252

G

kinesin family member C1

decreases expression

Bortezomib results in decreased expression of KIFC1 mRNA

NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105

G

KLF transcription factor 6

increases expression

Bortezomib results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kelch domain containing 7B

increases expression

Bortezomib results in increased expression of KLHDC7B mRNA

NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737

G

kelch-like family member 20

increases expression

Bortezomib results in increased expression of KLHL20 mRNA

NCBI chr13:73,363,451...73,408,293
Ensembl chr13:73,363,455...73,408,337

G

killer cell lectin like receptor K1

decreases expression

Bortezomib results in decreased expression of KLRK1 mRNA

NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459

G

lysine methyltransferase 2A

multiple interactions

[arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA

NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181

G

karyopherin subunit alpha 2

increases expression

Bortezomib results in increased expression of KPNA2 mRNA

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

KRI1 homolog

increases expression

Bortezomib results in increased expression of KRI1 mRNA

NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392

G

KRIT1, ankyrin repeat containing

increases expression

Bortezomib results in increased expression of KRIT1 mRNA

NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359

G

kinectin 1

increases expression

Bortezomib results in increased expression of KTN1 mRNA

NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578

G

galectin 2

decreases expression

Bortezomib results in decreased expression of LGALS2 mRNA

NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802

G

galectin 8

increases expression

Bortezomib results in increased expression of LGALS8 mRNA

NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA

NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899

G

DNA ligase 4

increases expression

Bortezomib results in increased expression of LIG4 mRNA

NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040

G

LIM domain and actin binding 1

increases expression

Bortezomib results in increased expression of LIMA1 mRNA

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

LIM domain containing 1

increases expression

Bortezomib results in increased expression of LIMD1 mRNA

NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714

G

LIM zinc finger domain containing 1

increases expression

Bortezomib results in increased expression of LIMS1 mRNA

NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500

G

lamin A/C

increases cleavage

Bortezomib results in increased cleavage of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

leucine rich repeat and fibronectin type III domain containing 4

decreases expression

Bortezomib results in decreased expression of LRFN4 mRNA

NCBI chr 1:201,888,569...201,891,861
Ensembl chr 1:201,888,569...201,891,861

G

leucine rich repeat containing 41

decreases expression

Bortezomib results in decreased expression of LRRC41 mRNA

NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449

G

LRR binding FLII interacting protein 1

increases expression

Bortezomib results in increased expression of LRRFIP1 mRNA

NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

Bortezomib results in decreased expression of LSM4 mRNA

NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926

G

leukocyte specific transcript 1

decreases expression

Bortezomib results in decreased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

LUC7-like

increases expression

Bortezomib results in increased expression of LUC7L mRNA

NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112

G

lymphocyte antigen 96

multiple interactions

[arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

LYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein

NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868

G

MAF1 homolog, negative regulator of RNA polymerase III

multiple interactions

Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249

G

MAF bZIP transcription factor G

increases expression

Bortezomib results in increased expression of MAFG mRNA

NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase kinase 1

multiple interactions

[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

decreases expression

Bortezomib results in decreased expression of MAP2K2 mRNA

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase kinase 4

multiple interactions

alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein

NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993

G

mitogen-activated protein kinase kinase 6

decreases expression

Bortezomib results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen-activated protein kinase kinase kinase kinase 3

increases expression

Bortezomib results in increased expression of MAP4K3 mRNA

NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334

G

mitogen-activated protein kinase kinase kinase kinase 4

increases expression

Bortezomib results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 1

multiple interactions
increases expression
increases phosphorylation
decreases activity

[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein

PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 10

multiple interactions

[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein]

NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201

G

mitogen activated protein kinase 14

multiple interactions

[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]

PMID:12893773 PMID:18790767

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases expression
increases phosphorylation
decreases activity

[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein

PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
evodiamine inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]

PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 More...

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases phosphorylation
multiple interactions

Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]

PMID:16985072 PMID:18559525 PMID:18718063

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MAPK associated protein 1

decreases expression

Bortezomib results in decreased expression of MAPKAP1 mRNA

NCBI chr 3:17,715,813...17,918,387
Ensembl chr 3:17,715,834...17,918,384

G

MAPK activated protein kinase 2

decreases expression

Bortezomib results in decreased expression of MAPKAPK2 mRNA

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

microtubule affinity regulating kinase 2

decreases expression

Bortezomib results in decreased expression of MARK2 mRNA

NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652

G

MYC associated zinc finger protein

decreases expression

Bortezomib results in decreased expression of MAZ mRNA

NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408

G

methyl-CpG binding domain protein 1

decreases expression

Bortezomib results in decreased expression of MBD1 mRNA

NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554

G

methyl-CpG binding domain 4 DNA glycosylase

increases expression

Bortezomib results in increased expression of MBD4 mRNA

NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982

G

mannose binding lectin 2

increases response to substance

MBL2 gene SNP results in increased susceptibility to Bortezomib

NCBI chr 1:228,016,439...228,024,736

G

muscleblind-like splicing regulator 1

decreases expression

Bortezomib results in decreased expression of MBNL1 mRNA

NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368

G

myelin basic protein

decreases expression

Bortezomib results in decreased expression of MBP mRNA

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
increases expression
decreases response to substance
increases cleavage

[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein

PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 More...

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

minichromosome maintenance complex component 7

decreases expression

Bortezomib results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

mediator of DNA damage checkpoint 1

decreases expression

Bortezomib results in decreased expression of MDC1 mRNA

NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240

G

MDM2 proto-oncogene

multiple interactions
increases cleavage
affects expression

[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

malic enzyme 1

increases expression

Bortezomib results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

methyltransferase 21A, HSPA lysine

increases expression

Bortezomib results in increased expression of METTL21A mRNA

NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550

G

methyltransferase like 27

decreases expression

Bortezomib results in decreased expression of METTL27 mRNA

NCBI chr12:21,757,545...21,766,698
Ensembl chr12:21,757,329...21,766,685

G

mex-3 RNA binding family member D

decreases expression

Bortezomib results in decreased expression of MEX3D mRNA

NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096

G

mitofusin 1

decreases expression

Bortezomib results in decreased expression of MFN1 mRNA

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

decreases expression

Bortezomib results in decreased expression of MFNG mRNA

NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein]

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microRNA 21

increases expression

Bortezomib results in increased expression of MIR21 mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

marker of proliferation Ki-67

decreases expression
multiple interactions

Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]

PMID:19372569 PMID:30482226

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

MLLT11, transcription factor 7 cofactor

increases expression

Bortezomib results in increased expression of MLLT11 mRNA

NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199

G

matrix metallopeptidase 9

multiple interactions

Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein]

PMID:20696233 PMID:24333736

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MOB kinase activator 3A

decreases expression

Bortezomib results in decreased expression of MOB3A mRNA

NCBI chr 7:9,010,490...9,027,888
Ensembl chr 7:9,010,587...9,027,879

G

MORC family CW-type zinc finger 2

increases expression

Bortezomib results in increased expression of MORC2 mRNA

NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343

G

myelin protein zero

decreases expression

Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein

NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679

G

mitochondrial ribosomal protein L19

increases expression

Bortezomib results in increased expression of MRPL19 mRNA

NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053

G

mitochondrial ribosomal protein L30

decreases expression

Bortezomib results in decreased expression of MRPL30 mRNA

NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257

G

mitochondrial ribosomal protein S12

decreases expression

Bortezomib results in decreased expression of MRPS12 mRNA

NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780

G

mitochondrial ribosomal protein S5

decreases expression

Bortezomib results in decreased expression of MRPS5 mRNA

NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291

G

mutS homolog 6

decreases expression

Bortezomib results in decreased expression of MSH6 mRNA

NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956

G

myotubularin related protein 6

increases expression

Bortezomib results in increased expression of MTMR6 mRNA

NCBI chr15:34,419,931...34,457,863
Ensembl chr15:34,419,903...34,457,861

G

mucin 1, cell surface associated

decreases expression

Bortezomib results in decreased expression of MUC1 mRNA

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

mutY DNA glycosylase

decreases expression

Bortezomib results in decreased expression of MUTYH mRNA

NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
increases expression
decreases expression

[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein

PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYD88, innate immune signal transduction adaptor

decreases expression

Bortezomib results in decreased expression of MYD88 mRNA

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

myosin light chain 12A

increases expression

Bortezomib results in increased expression of MYL12A mRNA

NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580

G

myosin VA

increases response to substance

MYO5A gene SNP results in increased susceptibility to Bortezomib

NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918

G

N(alpha)-acetyltransferase 80, NatH catalytic subunit

decreases expression

Bortezomib results in decreased expression of NAA80 mRNA

NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563

G

Ngfi-A binding protein 2

decreases expression

Bortezomib results in decreased expression of NAB2 mRNA

NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989

G

nucleic acid binding protein 1

increases expression

Bortezomib results in increased expression of NABP1 mRNA

NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107

G

NAD kinase

decreases expression

Bortezomib results in decreased expression of NADK mRNA

NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322

G

NAD kinase 2, mitochondrial

increases expression

Bortezomib results in increased expression of NADK2 mRNA

NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808

G

nuclear assembly factor 1 ribonucleoprotein

increases expression

Bortezomib results in increased expression of NAF1 mRNA

NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293

G

NLR family, apoptosis inhibitory protein 6

affects expression

Bortezomib affects the expression of NAIP mRNA

NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542

G

nucleosome assembly protein 1-like 2

increases expression

Bortezomib results in increased expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

neutrophil cytosolic factor 4

decreases expression

Bortezomib results in decreased expression of NCF4 mRNA

NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389

G

NCK-associated protein 1

increases expression

Bortezomib results in increased expression of NCKAP1 mRNA

NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217

G

nuclear receptor coactivator 3

increases expression

Bortezomib results in increased expression of NCOA3 mRNA

NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594

G

natural cytotoxicity triggering receptor 1

decreases expression

Bortezomib results in decreased expression of NCR1 protein

NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558

G

N-myc downstream regulated 1

increases expression

Bortezomib results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NDRG family member 3

decreases expression

Bortezomib results in decreased expression of NDRG3 mRNA

NCBI chr 3:145,587,505...145,650,896
Ensembl chr 3:145,548,041...145,650,873
Ensembl chr 3:145,548,041...145,650,873

G

NEDD1 gamma-tubulin ring complex targeting factor

increases expression

Bortezomib results in increased expression of NEDD1 mRNA

NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486

G

neuropilin and tolloid like 2

decreases expression

Bortezomib results in decreased expression of NETO2 mRNA

NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
increases activity

[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein
Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]
Bortezomib results in increased activity of NFE2L2 protein

PMID:20806931 PMID:30818834 PMID:35121005

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/A

decreases expression

Bortezomib results in decreased expression of NFIA mRNA

NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression
decreases expression

[Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]
Bortezomib results in increased expression of NFKB1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA]
Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein

PMID:12893773 PMID:16230421 PMID:17164350 PMID:17626072 PMID:18223231 More...

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nuclear factor kappa B subunit 2

decreases cleavage
decreases expression

Bortezomib results in decreased cleavage of NFKB2 protein
Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein

PMID:17626072 PMID:18223231 PMID:25913414

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation
increases stability
increases degradation
increases expression
decreases degradation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]
Bortezomib results in increased stability of NFKBIA protein
Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form
Bortezomib results in decreased degradation of NFKBIA protein

PMID:15039284 PMID:15543232 PMID:17895889 PMID:18089816 PMID:18223231 More...

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor beta

increases stability
increases expression

Bortezomib results in increased stability of NFKBIB protein
Bortezomib results in increased expression of NFKBIB mRNA

PMID:15543232 PMID:20977926 PMID:25913414

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

NFKB inhibitor epsilon

multiple interactions
increases stability

Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA]
Bortezomib results in increased stability of NFKBIE protein

PMID:15543232 PMID:20471514

NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437

G

nuclear transcription factor Y subunit gamma

decreases expression

Bortezomib results in decreased expression of NFYC mRNA

NCBI chr 5:134,336,802...134,405,372
Ensembl chr 5:134,336,808...134,405,377

G

nipsnap homolog 1

decreases expression

Bortezomib results in decreased expression of NIPSNAP1 mRNA

NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098

G

NLR family, pyrin domain containing 12

multiple interactions
increases expression

Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA]
Bortezomib results in increased expression of NLRP12 mRNA

NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934

G

NLR family, pyrin domain containing 3

decreases expression
increases expression
multiple interactions

Bortezomib results in decreased expression of NLRP3 mRNA
Bortezomib results in increased expression of NLRP3 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA]

PMID:17659339 PMID:35121005

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 1

increases expression
multiple interactions

Bortezomib results in increased expression of NOS1 protein
Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

notch receptor 2

decreases expression

Bortezomib results in decreased expression of NOTCH2 mRNA

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

nucleophosmin 1

multiple interactions
affects response to substance
increases response to substance

Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib]
NPM1 protein affects the susceptibility to Bortezomib

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
Ensembl chr X:17,739,941...17,751,645

G

neuronal pentraxin 1

decreases expression

Bortezomib results in decreased expression of NPTX1 mRNA

NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Bortezomib results in increased expression of NQO1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA]

PMID:20977926 PMID:35121005

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression

Bortezomib results in increased expression of NQO2 mRNA

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 1, group H, member 3

decreases expression

Bortezomib results in decreased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor interacting protein 3

increases expression

Bortezomib results in increased expression of NRIP3 mRNA

NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600

G

NS5A transactivated protein 4

decreases expression

Bortezomib results in decreased expression of C1ORF43 mRNA

NCBI chr 2:175,494,406...175,507,281
Ensembl chr 2:175,494,304...175,510,663

G

5'-nucleotidase, cytosolic II

increases expression

Bortezomib results in increased expression of NT5C2 mRNA

NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913

G

5' nucleotidase, ecto

decreases expression

Bortezomib results in decreased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

negative regulator of ubiquitin-like proteins 1

increases expression

Bortezomib results in increased expression of NUB1 mRNA

NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

decreases expression

Bortezomib results in decreased expression of NUCKS1 mRNA

NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229

G

NUMB, endocytic adaptor protein

increases expression

Bortezomib results in increased expression of NUMB mRNA

NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354

G

NUMB-like, endocytic adaptor protein

increases expression

Bortezomib results in increased expression of NUMBL mRNA